Researchers at CNIO and IRB Barcelona reveal the function of HAT proteins, which serve as gates for the cellular entry and exit of amino acids.
Using cryo-electron microscopy, they have uncovered the mechanisms by which some HAT proteins transport certain amino acids and not others.
These results help to understand why distinct HAT proteins participate in specific diseases such as cancer in some cases, or neurological diseases such as strokes, Alzheimer´s disease, and deafness in others.
The researchers now face the challenge of disrupting these proteins to treat these diseases, which pose a serious health problem.
The proteins that belong to the HAT family are essential for life as they transport amino acids across the cell membrane. Although the members of this family are practically identical, some transport certain amino acids and not others. This specialisation determines their involvement in specific functions, such as cell growth or neuronal functions, and consequently in related diseases like cancer or neurodegenerative conditions such as Alzheimer´s disease. What confers this specificity and diversity of functions? This is one of the questions asked by researchers at the Spanish National Cancer Research Center (CNIO) and the Institute for Research in Biomedicine (IRB Barcelona), who led the study, and one whose answer has been published this week in the journal Proceedings of the National Academy of Sciences (PNAS).
Thanks to the latest high-resolution structural technologies such as cryo-electron microscopy, combined with computational modelling and the design of mutants of these proteins, the researchers have been able to observe the structure of one of the members of this protein family in atomic detail and decipher its function. The results of the study show how only a few residues—located in defined regions—of this family of proteins select the specific amino acids to which they will bind and are therefore responsible for the protein to participate in specific physiological functions.
Armed with this information, the researchers now face the challenge of finding new therapies and diagnostic tools for diseases that involve the HAT family of transporter proteins, with a particular interest in those conditions that pose serious health problems, such as cancer and neurodegenerative disorders such as Alzheimer´s disease.
Understanding how to disrupt their function
Amino acids, the basic building blocks of life, enter and leave cells, enabling them to grow, divide and develop their functions. This movement into and out of the cell occurs thanks to gates embedded in the cell membrane that are formed by proteins of the HAT family, among others.
Although HAT proteins are practically identical in structure, some transport certain amino acids and not others, thereby conferring each member of the family specific functions, such as the participation in cell growth; a role in diseases such as cancer; neuronal functions; and the transport of toxic substances and involvement in addiction to substances such as cocaine.
To understand this specificity of function, the scientists set out to study the 3D structure of this important family of proteins. "Classical techniques used to determine the structure of proteins, such as those using X-rays, have had limited success with proteins that are embedded in biological membranes, and so many questions have remained unresolved," says Oscar Llorca, head of the Macromolecular Complexes in DNA Damage Response Group at CNIO, Director of the Structural Biology Programme of this Centre and co-author of the work.
"The combination of structural resolution by cryo-electron microscopy with molecular dynamics calculations and functional studies provides an experimental platform with a lot of potential that allows us to unravel the function of amino acid transporters. In this case, we have applied this technology to identify the molecular mechanisms that lead these proteins to transport some amino acids but not others," says Manuel Palacín, head of the Amino Acid Transporters and Disease laboratory at IRB Barcelona, professor of the University of Barcelona and Unit leader of CIBERER.
New drugs against cancer and Alzheimer´s disease
Thanks to cryo-electron microscopy, a field in which Llorca is an international expert, visualisation of the molecular structure of proteins has taken a giant step towards what we now know as the golden age of 3D structures. This new technology, which won the Nobel Prize in Chemistry in 2017, has not only served to observe biological processes like never before but it is also contributing to accelerating the development of new compounds and drugs of interest to treat cancer and other human diseases.
In this work, using cryo-electron microscopy, the researchers have been able to visualise the structure of a member of the HAT family at atomic resolution and determine the pocket where these proteins bind to amino acids, as well as the details of the mechanism by which this recognition occurs.
The atomic details reveal that only a few residues of these proteins determine the amino acids to which they bind and therefore their specific functions. In addition, the study demonstrates how the substitutions of some residues for others in these positions in the different members of the family are responsible for modifying the specificity of recognition and transport of some amino acids and not others.
The results of this research will now allow efforts to be directed towards compounds that could act on specific regions of these proteins, and to manage the disorders in which they participate, such as cancer and neurodegenerative diseases like Alzheimer's disease.
Led by IRB Barcelona and CNIO, the study has been carried out in collaboration with the groups headed by Víctor Guallar, at the Barcelona Supercomputing Center (BSC) and Lucía Díaz, at the biotech Nostrum Biodiscovery.
The study has been possible thanks to the funding from the "la Caixa" Foundation, which, through its CaixaResearch program, promotes the best initiatives to tackle diseases that cause the greatest impact worldwide, such as cardiovascular, neurological, infectious and oncological conditions.
The study has also received funding from the Ministry of Science and Innovation, the Instituto de Salud Carlos III, the Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), the European Regional Development Fund, and the Government of Catalonia.
Carlos F Rodriguez*, Paloma Escudero-Bravo*, Lucía Díaz, Paola Bartoccioni, Carmen García-Martín, Joan G Gilabert, Jasminka Boskovic, Víctor Guallar, Ekaitz Errasti-Murugarren&, Oscar Llorca& and Manuel Palacín& (* co-primeros autores; & co- autores de correspondencia).
Structural basis for substrate specificity of heteromeric transporters of neutral amino acids
Proceedings of the Natural Academy of Science USA (2021) DOI: 10.1073/pnas.2113573118
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to offer pioneering solutions to unresolved medical needs in cancer and other diseases related to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 employees and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).